Clinical Trial Update: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update describes evaluating rituximab in combination with zanubrutinib for indolent B-cell lymphomas, including follicular lymphoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Rituximab (Rituxan) (rituximab)
• Zanubrutinib (Brukinsa) (zanubrutinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING